AOTMiT: Transparency Council on lung cancer, heart failure and obesity, among others

The agenda includes:

1 Prepare a position on the removal of the health care service "Collection of material from the cervix for cytological screening (classic cytology)".

2 Prepare a position paper on the evaluation of the drug Alecensa (alectinib) under the drug program "Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)".

3 Prepare a position paper on the evaluation of the drug Forxiga (dapagliflozinum) for the indication: chronic heart failure.

4. Preparation of a position paper on the examination of the legitimacy of issuing approvals for reimbursement of medicinal products containing the active substance cholestyramine for the indications: chronic diarrhea; Hirschsprung's disease; Crohn's disease; severe intestinal malabsorption caused by: resection of a segment of the small intestine, enterostomy; dyslipidemia, including hypercholesterolemia in patients who cannot receive statins; primary biliary cirrhosis; primary sclerosing cholangitis; pruritus in the course of: Alagille syndrome, cholestatic drug-induced hepatitis, intrahepatic cholestasis, resection of a portion of the large intestine; secondary cirrhosis with features of cholestasis following HCV infection.

5 Prepare a position paper on the examination of the legitimacy of issuing approvals for reimbursement of the medicinal product Attentin (dextroamphetamine) for the indication: attention deficit hyperactivity disorder (ADHD).

6 Prepare an opinion on the draft health policy program of the local government unit "NASTROIMY ŁÓDZKIE" program on mood disorders and neurotic, stress-related and somatoform disorders (Lodz province).

7 Prepare an opinion on the draft health policy program of the local government unit "Comprehensive program to prevent overweight and obesity in children and adolescents in Pomeranian voivodeship".

8. preparing an opinion on the draft health policy program of the local government unit "Od-Waga - Comprehensive treatment of overweight and obesity in children and adolescents" (city of Radom).

9. preparation of an opinion on the continuation of reimbursement in off-label indications for medicinal products containing the active substance cabozantinib, for the indication: in monotherapy in the treatment of hepatocellular carcinoma (HCC) in adults after previous ineffective treatment with tyrosine kinase inhibitors or immunotherapy in combination with antiangiogenic therapy or intolerance thereof, provided that clinically significant side effects of the previously used therapy have subsided, within the framework of the drug program: B.5 "Treatment of patients with hepatocellular carcinoma (ICD-10 C 22.0)".

10. Prepare an opinion on the continuation of reimbursement in off-label indications for medicinal products containing the active substance colistimethatum natricum in the indication: infections of the lower respiratory tract - supportive treatment in combination with intravenous antibiotic therapy in people after lung transplantation in the course of diseases other than cystic fibrosis.

11. Preparation of an opinion on continuation of reimbursement in off-label indications for medicinal products containing the active substance itraconazolum in the indication: fungal infections in patients after bone marrow transplantation - prophylaxis.

Source: AOTMiT